Lilly shares jump as analysts see retatrutide data extending obesity market edge

June 8 (Reuters) – Eli Lilly shares jumped 4% premarket on Monday, driven by compelling new data for its next-generation obesity drug, retatrutide, with analysts and investors expecting it to extend

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)